Clinical trials only work if people show up, and keep showing up, through months of visits, tests, and follow-ups. But for many participants, showing up costs real money. Gas, parking, missed shifts, a babysitter for the afternoon. Sponsors, CRO finance teams, and site administrators often underestimate the extent to which these costs shape who enrolls, who drops out, and who never applies at all.
Key Takeaways
- Travel, lost wages, and childcare costs push many eligible participants out of trials before they even enroll.
- Sponsor guidelines on participant payments vary widely, which creates confusion for sites and inconsistent experiences for patients.
- Lower-income patients are significantly less likely to join trials when reimbursement is slow or unclear.
- Standard-of-care coverage gaps add another layer of financial risk that discourages participation.
- Faster, more transparent payment systems help sponsors retain participants and build more representative trial populations.
What Participation Actually Costs
A trial visit rarely costs just the visit. Participants often pay for parking, mileage, or a flight if the site sits hours away. Add a hotel stay for an overnight protocol, a missed day of hourly wages, or a few hours of paid childcare, and a single visit can run into the hundreds of dollars. Multiply that across a year-long study with monthly visits, and the total burden adds up fast, especially for people already living paycheck to paycheck.
That math gets worse for participants who need overnight stays for multi-day protocols, or who travel from rural areas without a trial site nearby. A family covering two or three visits a month on top of regular bills can end up in real debt just for showing up, before the cost of the treatment or procedure even enters the picture.
Sponsors typically split these costs into three categories: reimbursement for expenses, compensation for time and effort, and incentive payments meant to encourage retention. The distinction between disbursement and reimbursement is often lost in practice, as some study teams use the terms interchangeably, while others treat them as entirely separate line items with different approval steps. That inconsistency delays payments and leaves participants guessing about when their money will actually show up.
Why the Inconsistency Hurts Enrollment
Confusing payment structures not only frustrate people; they also keep people out. Research shows lower-income patients are significantly less likely to join cancer trials than higher-income patients, largely because the upfront and ongoing costs outweigh what they expect to get back. Oncology trials in particular have been slow to offer compensation for time and effort, based on an old assumption that access to an experimental drug is payment enough. For someone weighing whether trial participation fits into an already stretched budget, that assumption does not hold up.
Federal guidance on research participant payments leaves sponsors with real discretion, which is part of why practices differ so much from one study to the next. Program administrators are often left interpreting broad language without a clear industry standard to point to.
Sites that want to close that gap are rethinking how payments move from sponsor to participant in the first place, and a closer look at Rellevate’s disbursement solutions shows what that can look like in practice.
Where Standard of Care Coverage Falls Short
Insurance coverage for standard-of-care procedures during a trial is supposed to work the same as it would outside the trial. In reality, coverage varies by plan, by state, and by how a particular procedure gets coded. A participant with a high deductible plan can face thousands of dollars in out-of-pocket costs before a sponsor’s reimbursement ever kicks in, and most people are not told what that number might be before they enroll.
Understanding trial participation costs matters just as much to program administrators as it does to the patients deciding whether to enroll, since every dropout adds delay and expense to a study that is already running on a fixed timeline. That kind of financial uncertainty is enough to make even a motivated candidate walk away.
Modern Trial Models Raise the Stakes
The shift toward decentralized clinical trials adds another layer to this. When participants complete visits at home or at a local clinic rather than at a single central site, sponsors need payment systems that can reach people across dozens of locations, not just a single building. That means digital payment services built for speed and traceability, not paper checks that take weeks to arrive and even longer to reconcile.
Sponsors evaluating cash disbursement alternatives are finding that digital transfers cut processing time from weeks to days, which matters when a participant is counting on the reimbursement to cover a bill that has already come due.
Building Payment Systems Sponsors and Sites Can Trust
For teams managing payments across a growing number of remote and hybrid sites, Rellevate’s healthcare disbursement tools help standardize the process without adding headcount.
None of this requires reinventing how trials run. It requires sponsors, CROs, and sites to agree on shared language for what counts as reimbursement versus compensation, and to build payment systems that can prove a participant was paid on time. Digital platforms that let participants track their own payments reduce the phone calls and email chains that eat up site staff time. And when finance and clinical operations teams work from the same payment data, budget forecasting involves a lot less guesswork.
A few practical steps make the biggest difference. Setting one shared definition of reimbursement versus compensation across a sponsor’s studies. Processing payments in days instead of weeks. Giving site staff a simple way to check payment status instead of chasing it down by phone. None of these changes are complicated, but they require someone at the sponsor or CRO level to actually own the payment process rather than leaving each site to sort it out on its own.
Every dollar a trial participant spends out of pocket is a small bet against retention. Sponsors and sites that treat payment speed and clarity as part of the study design, not an afterthought, tend to see this reflected in enrollment numbers and completion rates. The organizations getting this right are not necessarily spending more. They are just making sure the money moves as reliably as the protocol does.
